Literature DB >> 20617921

Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC.

Rochelle P Walensky1, A David Paltiel, Elena Losina, Bethany L Morris, Callie A Scott, Erin R Rhode, George R Seage, Kenneth A Freedberg.   

Abstract

BACKGROUND: The United States and international agencies have signaled their commitment to containing the human immunodeficiency virus (HIV) epidemic via early case identification and linkage to antiretroviral therapy (ART) immediately at diagnosis. We forecast outcomes of this approach if implemented in Washington DC.
METHODS: Using a mathematical model of HIV case detection and treatment, we evaluated combinations of HIV screening and ART initiation strategies. We define current practice as no regular screening program and ART at CD4 counts < or = 350 cells/microL, and we define test and treat as annual screening and administration of ART at diagnosis. Outcomes include life expectancy of HIV-infected persons and changes in the population time with transmissible HIV RNA levels. Data, largely from Washington DC, include undiagnosed HIV prevalence of 0.6%, annual incidence of 0.13%, 31% rate of test offer, 60% rate of acceptance, and 50% linkage to care. Input parameters, including optimized ART efficacy, are varied in sensitivity analyses.
RESULTS: Projected life expectancies, from an initial mean age of 41 years, are 23.9, 25.0, and 25.6 years for current practice, test and treat, and test and treat with optimized ART, respectively. Compared with current practice, test and treat leads to a 14.7% reduction in time spent with transmissible HIV RNA level in the next 5 years; test and treat with optimized ART results in a 27.3% reduction.
CONCLUSIONS: An expanded HIV test and treat program in Washington DC will increase life expectancy of HIV-infected patients but will have a modest impact on HIV transmission over the next 5 years and is unlikely to halt the HIV epidemic.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20617921      PMCID: PMC2906630          DOI: 10.1086/655130

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  27 in total

1.  Preventing HIV transmission with antiretrovirals.

Authors:  Kevin M De Cock; Siobhan P Crowley; Ying-Ru Lo; Reuben M Granich; Brian G Williams
Journal:  Bull World Health Organ       Date:  2009-07       Impact factor: 9.408

2.  Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.

Authors:  J W Mellors; A Muñoz; J V Giorgi; J B Margolick; C J Tassoni; P Gupta; L A Kingsley; J A Todd; A J Saah; R Detels; J P Phair; C R Rinaldo
Journal:  Ann Intern Med       Date:  1997-06-15       Impact factor: 25.391

3.  The cost effectiveness of combination antiretroviral therapy for HIV disease.

Authors:  K A Freedberg; E Losina; M C Weinstein; A D Paltiel; C J Cohen; G R Seage; D E Craven; H Zhang; A D Kimmel; S J Goldie
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

4.  Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

Authors:  Paul E Sax; Camlin Tierney; Ann C Collier; Margaret A Fischl; Katie Mollan; Lynne Peeples; Catherine Godfrey; Nasreen C Jahed; Laurie Myers; David Katzenstein; Awny Farajallah; James F Rooney; Belinda Ha; William C Woodward; Susan L Koletar; Victoria A Johnson; P Jan Geiseler; Eric S Daar
Journal:  N Engl J Med       Date:  2009-12-01       Impact factor: 91.245

5.  Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection.

Authors:  Vikram S Gill; Viviane D Lima; Wen Zhang; Brian Wynhoven; Benita Yip; Robert S Hogg; Julio S G Montaner; P Richard Harrigan
Journal:  Clin Infect Dis       Date:  2010-01-01       Impact factor: 9.079

6.  High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

Authors:  Y Yazdanpanah; C Fagard; D Descamps; A M Taburet; C Colin; B Roquebert; C Katlama; G Pialoux; C Jacomet; C Piketty; D Bollens; J M Molina; G Chêne
Journal:  Clin Infect Dis       Date:  2009-11-01       Impact factor: 9.079

7.  Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy.

Authors:  Rochelle P Walensky; Sue J Goldie; Paul E Sax; Milton C Weinstein; A David Paltiel; April D Kimmel; George R Seage; Elena Losina; Hong Zhang; Runa Islam; Kenneth A Freedberg
Journal:  J Acquir Immune Defic Syndr       Date:  2002-09-01       Impact factor: 3.731

8.  Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.

Authors:  Luigia Elzi; Catia Marzolini; Hansjakob Furrer; Bruno Ledergerber; Matthias Cavassini; Bernard Hirschel; Pietro Vernazza; Enos Bernasconi; Rainer Weber; Manuel Battegay
Journal:  Arch Intern Med       Date:  2010-01-11

9.  A comparison of HIV testing in the emergency department and urgent care.

Authors:  Douglas A E White; Paul T Cheung; Alicia N Scribner; Bradley W Frazee
Journal:  J Emerg Med       Date:  2009-07-09       Impact factor: 1.484

10.  Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study.

Authors:  Evan Wood; Thomas Kerr; Brandon D L Marshall; Kathy Li; Ruth Zhang; Robert S Hogg; P Richard Harrigan; Julio S G Montaner
Journal:  BMJ       Date:  2009-04-30
View more
  66 in total

1.  Integrating acute HIV infection within routine public health surveillance practices in New York City.

Authors:  Sara Bodach; Sarah Braunstein; Marie Antoinette Bernard; Charulata Jain Sabharwal; Adey Tsega; Colin Shepard
Journal:  Public Health Rep       Date:  2012 Jul-Aug       Impact factor: 2.792

Review 2.  Is expanded HIV treatment preventing new infections? Impact of antiretroviral therapy on sexual risk behaviors in the developing world.

Authors:  Kartik K Venkatesh; Timothy P Flanigan; Kenneth H Mayer
Journal:  AIDS       Date:  2011-10-23       Impact factor: 4.177

3.  Mobile Health Intervention to Reduce HIV Transmission: A Randomized Trial of Behaviorally Enhanced HIV Treatment as Prevention (B-TasP).

Authors:  Seth C Kalichman; Chauncey Cherry; Moira O Kalichman; Lisa A Eaton; James J Kohler; Catherine Montero; Raymond F Schinazi
Journal:  J Acquir Immune Defic Syndr       Date:  2018-05-01       Impact factor: 3.731

Review 4.  Antiretroviral therapy: a key component of a comprehensive HIV prevention strategy.

Authors:  Mark W Hull; Julio Montaner
Journal:  Curr HIV/AIDS Rep       Date:  2011-06       Impact factor: 5.071

5.  Antiretroviral therapy as prevention: linking the mainframe to Main Street.

Authors:  Victor DeGruttola; Robert T Schooley
Journal:  Clin Infect Dis       Date:  2011-04-15       Impact factor: 9.079

6.  Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.

Authors:  Rochelle P Walensky; Paul E Sax; Yoriko M Nakamura; Milton C Weinstein; Pamela P Pei; Kenneth A Freedberg; A David Paltiel; Bruce R Schackman
Journal:  Ann Intern Med       Date:  2013-01-15       Impact factor: 25.391

Review 7.  Clinical uncertainties, health service challenges, and ethical complexities of HIV "test-and-treat": a systematic review.

Authors:  Sonali P Kulkarni; Kavita R Shah; Karthik V Sarma; Anish P Mahajan
Journal:  Am J Public Health       Date:  2013-04-18       Impact factor: 9.308

8.  The Anticipated Clinical and Economic Effects of 90-90-90 in South Africa.

Authors:  Rochelle P Walensky; Ethan D Borre; Linda-Gail Bekker; Stephen C Resch; Emily P Hyle; Robin Wood; Milton C Weinstein; Andrea L Ciaranello; Kenneth A Freedberg; A David Paltiel
Journal:  Ann Intern Med       Date:  2016-05-31       Impact factor: 25.391

9.  The association between poor antiretroviral adherence and unsafe sex: differences by gender and sexual orientation and implications for scale-up of treatment as prevention.

Authors:  Robert H Remien; Curtis Dolezal; Glenn J Wagner; Kathy Goggin; Ira B Wilson; Robert Gross; Marc I Rosen; Jie Shen; Jane M Simoni; Carol E Golin; Julia H Arnsten; David R Bangsberg; Honghu Liu
Journal:  AIDS Behav       Date:  2014-08

10.  Test-and-treat in Los Angeles: a mathematical model of the effects of test-and-treat for the population of men who have sex with men in Los Angeles County.

Authors:  Neeraj Sood; Zachary Wagner; Amber Jaycocks; Emmanuel Drabo; Raffaele Vardavas
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.